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The role of the host in development of persistent methicillin-
resistant Staphylococcus aureus (MRSA) bacteremia is not well un-
derstood. A cohort of prospectively enrolled patients with persis-
tent methicillin-resistant S. aureus bacteremia (PB) and resolving
methicillin-resistant S. aureus bacteremia (RB) matched by sex, age,
race, hemodialysis status, diabetes mellitus, and presence of implant-
able medical device was studied to gain insights into this question.
One heterozygous g.25498283A > C polymorphism located in the
DNMT3A intronic region of chromosome 2p with no impact in mes-
senger RNA (mRNA) expression was more common in RB (21 of 34,
61.8%) than PB (3 of 34, 8.8%) patients (P= 7.8 × 10−6). Patients with
MRSA bacteremia and g.25498283A > C genotype exhibited signif-
icantly higher levels of methylation in gene-regulatory CpG island
regions (Δmethylation = 4.1%, P < 0.0001) and significantly lower
serum levels of interleukin-10 (IL-10) than patients with MRSA bac-
teremia without DNMT3A mutation (A/C: 9.7038 pg/mL vs. A/A:
52.9898 pg/mL; P = 0.0042). Expression of DNMT3A was signifi-
cantly suppressed in patients with S. aureus bacteremia and in S.
aureus-challenged primary human macrophages. Small interfering
RNA (siRNA) silencing of DNMT3A expression in human macro-
phages caused increased IL-10 response upon S. aureus stimula-
tion. Treating macrophages with methylation inhibitor 5-Aza-2′-
deoxycytidine resulted in increased levels of IL-10 when challenged
with S. aureus. In the murine sepsis model, methylation inhibition
increased susceptibility to S. aureus. These findings indicate
that g.25498283A > C genotype within DNMT3A contributes
to increased capacity to resolve MRSA bacteremia, potentially
through a mechanism involving increased methylation of gene-
regulatory regions and reduced levels of antiinflammatory
cytokine IL-10.
Staphylococcus aureus | MRSA | persistence | host genetics | DNMT3A
Persistent methicillin-resistant Staphylococcus aureus (MRSA)bacteremia in patients despite appropriate antibiotic therapy
is common, incompletely understood, and associated with poor
clinical outcome (1–3). A growing body of evidence indicates
that genetic variation may influence patient risk for S. aureus
infection (4–7). In this investigation, we used a comprehensive
approach to identify potential host genetic determinants of per-
sistent methicillin-resistant S. aureus bacteremia (PB) and resolv-
ing methicillin-resistant S. aureus bacteremia (RB) in a large
cohort of patients with S. aureus bacteremia (SAB). First, patients
with PB and RB were matched on important clinical variables to
minimize potential confounding factors. Second, we used whole-
exome sequencing (WES) to identify candidate genetic variants
associated with PB and RB. Third, we interrogated the PB and RB
patient groups for differences in epigenetic phenomena, whole-blood
gene expression levels, and serum cytokine levels to establish a
potential pathogenic mechanism for any associations found in
the WES. Fourth, we performed in vitro and in vivo experi-
ments to support the biological plausibility of our findings.
Significance
The severity and duration of methicillin-resistant Staphylo-
coccus aureus (MRSA) bacteremia varies widely between indi-
viduals. Host factors predisposing to persistentMRSA bacteremia
are poorly understood, although genetic association studies are
beginning to identify potentially influential variants. We found
an association between the A/C heterozygous genotype in the
DNMT3A correlating with shorter time to resolution of MRSA
bacteremia. Using in vitro macrophage assays and murine sepsis
models, we demonstrated that DNMT3A variants may alter host
response to infection through increased methylation of key
regulatory genes, resulting in reduced interleukin-10 production
and in turn, allowing for a more protective immune response
that clears infection. An improved understanding of the factors
predisposing to persistent MRSA bacteremia may help to dis-
cover better treatment options.
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Results
Clinical Cohort.A total of 68 patients with PB or RB were matched
1:1 by sex, age (in deciles), race, hemodialysis status, diabetes
mellitus, and presence of implantable medical device (Table 1).
One Polymorphism in DNMT3A Differentiates between Persistent and
Resolving MRSA Bacteremia. To test whether host genetic variation
is associated with development of the PB phenotype, WES was
performed on the 68 study patients (8). The most significantly
associated variant was a single-nucleotide polymorphism (SNP),
g.25498283A > C, which is located in the DNMT3A intronic
region of chromosome 2p. The SNP was more common in RB
(21 of 34, 61.8%) than PB (3 of 34, 8.8%) with a P value of 7.8 ×
10−6, which is just above a Bonferroni-corrected genome-wide
level of significance (1.2 × 10−7) (Fig. 1 and SI Appendix, Table
S1). The g.25498283A > C mutation overlaps with open chro-
matin regions and known transcription factors (SP1 and EGR1)
binding sites (9), suggesting that the variant might be located
within a regulatory region of DNMT3A. Given the role of
DNMT3A in host immune response (10) and the fact that de-
mographic characteristics of patients with and without the SNP
were similar (SI Appendix, Table S2), we further pursued 2 lines
of investigation: 1) the potential involvement of DNMT3A in
host response to S. aureus infection and 2) the potential role of
variation within DNMT3A in patients with PB vs. RB.
DNMT3A Is Involved in Host Response to S. aureus Infection. To
evaluate the clinical relevance of DNMT3A in host response to S.
aureus, we first compared the impact of S. aureus infection on
DNMT3A expression using existing whole-blood microarray ex-
pression data from our previously published cohort of patients
with SAB (n = 32) or Escherichia coli (n = 19) bacteremia (11).
Relative to healthy controls, DNMT3A expression was signifi-
cantly suppressed in patients with SAB but not E. coli bacteremia
(Fig. 2A). Transcription of DNMT3A was also suppressed when
we challenged primary human macrophages with S. aureus in
vitro (Fig. 2B). Using publicly available Gene Expression Om-
nibus (GEO) datasets, DNMT3A transcription was suppressed at
all tested time points in S. aureus-challenged human macrophages
(12) (Fig. 2C) and at 2 and 3 h postinfection in S. aureus-
challenged human neutrophils (13) (Fig. 2D). These data collec-
tively suggest a potential role ofDNMT3A in promoting protective
immune responses to S. aureus infection and potential S. aureus-
mediated dysregulation of such responses.
Patients with g.25498283A > C Exhibit Higher Methylation Levels in
Gene Regulatory CpG Island Regions.We next tested whether DNA
methylation patterns differed between patients with and without
the g.25498283A > C mutation using reduced representation bi-
sulfite sequencing (RRBS). The DNA methylation profile exhibi-
ted a bimodal distribution. To study the global methylation pattern
at the population level, we investigated the average methylation
level of each CpG region within patients with and without
g.25498283A > C mutation. Study patients with the g.25498283A >
C genotype exhibited significantly higher levels of methylation in
gene-regulatory CpG island regions than patients with the homo-
zygote genotype (Δmethylation = 4.1%, P < 0.0001) (Fig. 3). These
results suggest that a global methylation increase at gene-regulatory
regions is associated with the observed g.25498283A > C mutation
in DNMT3A, and introduce a potential mechanism by which this
mutation could influence host ability to resolve MRSA bacteremia.
DNMT3A Expression Levels Were Similar in Patients with and without
g.25498283A > C. Next, we performed whole-blood gene expres-
sion analysis to consider whether the DNMT3A genotype influ-
enced expression levels. No significant differences in DNMT3A
expression were noted between patients with (n = 24) or without
(n = 44) g.25498283A > C mutation (SI Appendix, Fig. S1A).
However, as the SNP of interest occurs within a noncoding region,
it is possible that the mode of action occurs via a change in ex-
pression or activity of a regulatory RNA species. To test this
possibility, we interrogated RNA sequencing (RNA-seq) data for
the expression of regulatory RNA species. We found 2 RNA
segments that were known to influence the DNMT3A promoter:
NUP153, which has been shown to bind outside of the catalytic
domain of DNMT3A with no effect in the DNMT3A activity, and
CDH1 (E-cadherin), which binds to the catalytic domain and in-
hibits DNMT3A activity (14). When we compared the expression
levels for NUP153 and CDH1 between the patients with and
without the polymorphism of interest, we found no significant
differences between the 2 populations. Collectively, these findings
suggest that the mechanism by which the DNMT3A poly-
morphism contributes to resolving MRSA bacteremia is not due
to differences in regulatory RNA species, although the num-
ber of samples available for this analysis was limited (A/A, n = 1;
A/C, n = 2) (SI Appendix, Fig. S1 B and C)
Patients with g.25498283A > C Exhibit Lower Levels of Interleukin-
10 than Patients without the SNP. The Th2 antiinflammatory cy-
tokine interleukin-10 (IL-10) has been previously shown to be
significantly elevated in patients with poor clinical outcome
among SAB patients, including mortality (15, 16), endovascular
infection (17), and PB (15), and was also significantly higher in
PB patients in our study (PB: 114.7472 pg/mL vs. RB: 13.1849
pg/mL; P = 0.0009).* Thus, we hypothesized that patients het-
erozygous for DNMT3A g.25498283A > C, who were signifi-
cantly less likely to exhibit PB, would also have significantly
lower levels of IL-10. To test this hypothesis, we measured IL-
10 levels in acute-phase serum from the study patients using a
Luminex-based 38-plex cytokine assay (SI Appendix, Fig. S2).
Consistent with our hypothesis, patients who were A/C hetero-
zygotes had significantly lower serum levels of IL-10 (A/C: 9.70
pg/mL vs. A/A: 52.99 pg/mL; P = 0.0042) than A/A patients
without the DNMT3A mutation (Fig. 4). This pattern of lower
IL-10 among heterozygotes occurred among both patients with
PB (A/C: 16.88 pg/mL vs. A/A: 68.94 pg/mL) and patients with
RB (A/C: 8.68 pg/mL vs. A/A: 14.95 pg/mL), although the small
number of A/C patients who developed PB (n = 3) limited sta-
tistical comparisons. These findings suggest our working model
in which patients with the A/C heterozygote genotype ofDNMT3A
were more likely to resolve MRSA bacteremia in part due to lower
levels of IL-10 regulated through higher levels of methylation in
gene-regulatory regions (Fig. 5).
Small Interfering RNA Knockdown of DNMT3A Increases IL-10
Production in Human Macrophages. We next sought to assemble
biological evidence to support the plausibility of this working
model. To further define the role of DNMT3A in regulation of
the macrophage response to S. aureus infection, cells were treated
with small interfering RNA (siRNA) specific to DNMT3A. Suc-
cessful knockdown of DNMT3A was confirmed by qRT-PCR (SI
Appendix, Fig. S3). Macrophages were then stimulated with S.
aureus, and a Luminex-based 10-plex cytokine assay was used to
evaluate the impact of DNMT3A knockdown on the macrophage
inflammatory response to S. aureus. Although the expression of
several cytokines was affected, only IL-10 levels were significantly
altered among S. aureus-challenged human macrophages with
siRNA-mediated knockdown of DNMT3A (siRNA knockdown:
232.63 pg/mL vs. scramble: 98.40 pg/mL; P = 0.0209) (Fig. 6A and
SI Appendix, Fig. S4A).
*M. Rossetti et al., “Early cytokine signatures discriminate persistent from resolving MRSA
bacteremia” in Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
(FOCIS, Menomonee Falls, WI, 2018), Abstract W.104.
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Table 1. Characteristics of patients with persistent and resolving MRSA bacteremia
PB, n = 34 RB, n = 34 Fisher P value
Characteristic
Age, median (P25, P75) 63 (55, 69) 61.5 (53, 70) 0.9462
Sex, no.(%) 1.00000
Male 23 (67.6) 23 (67.6)
Female 11 (32.4) 11 (32.4)
Race, no. (%) 1.00000
White 18 (52.9) 17 (50)
African American 16 (47.1) 16 (47.1)
Unknown 0 (0.0) 1(2.9)
Underlying comorbidity, no. (%)
Neoplasm 0 (0.0) 11 (32.4) 0.00037
Diabetic 17 (50) 20 (58.8) 0.62666
Hemodialysis dependent 13 (38.2) 9 (26.5) 0.43722
HIV positive 2 (5.9) 0 (0.0) 0.49254
Transplant recipient 1 (2.9) 6 (17.6) 0.10543
Injection drug use 1 (2.9) 0 (0.0) 1.00000
Corticosteroid use (30 d) 8 (23.5) 9 (26.5) 1.00000
Surgery past 30 d 7 (20.6) 9 (26.5) 0.77568
Endocarditis, previous episode 1 (2.9) 1 (2.9) 1.00000
Site of acquisition, no. (%) 0.52113
Hospital acquired 2 (5.9) 5 (14.7)
HCA community acquired 30 (88.2) 26 (76.5)
Non-HCA community acquired 2 (5.9) 3 (8.8)
Source of bacteremia, no.(%) 0.20791
Endovascular infection 12 (35.3) 6 (17.6)
GI/GU infection 4 (11.8) 8 (23.5)
Respiratory/lung 2 (5.9) 1 (2.9)
Skin, soft tissue, joint/bone infection 12 (35.3) 10 (29.4)
None/unknown 4 (11.8) 9 (26.5)
Other
Metastatic infection, no. (%) 25 (73.5) 14 (41.2) 0.01356
Metastatic abscess 6 (18.2) 3 (8.8) 0.30467
Metastatic arthritis 5 (15.2) 1 (2.9) 0.10543
Metastatic epidural abscess 3 (9.1) 1 (2.9) 0.35591
Metastatic vertebral osteomyelitis 5 (15.2) 1 (2.9) 0.10543
Metastatic nonvertebral osteomyelitis 5 (15.2) 3 (8.8) 0.47628
Metastatic psoas abscess 3 (9.1) 2 (5.9) 0.67284
Metastatic septic emboli 5 (15.2) 1 (2.9) 0.10543
Metastatic septic thrombophlebitis 1 (3) 1 (2.9) 1.00000
Metastatic kidney abscess 0 (0.0) 2 (5.9) 0.49254
Metastatic endocarditis 10 (30.3) 3 (8.8) 0.03331
APACHE II, mean (SD) 18.3 (7.7) 15.8 (4.5)
LOS categories, d, no. (%) 0.00010
<9 0 (0.0) 13 (38.2)
9–14 9 (26.5) 10 (29.4)
15–20 13 (38.2) 5 (14.7)
>20 12 (35.3) 6 (17.6)
Type of procedures used to treat the
infection, no. (%)
Surgical removal of foreign device 21 (67.7) 9 (40.9) 0.09057
Surgical debridement 11 (35.5) 2 (9.1) 0.04965
Surgical insertion of foreign device 4 (12.9) 3 (13.6) 1.00000
Abscess drainage 6 (19.4) 5 (22.7) 1.00000
Other 15 (48.4) 17 (77.3) 0.04752
Outcome (90 d), no. (%) 0.08432
Cure 27 (79.4) 33 (97.1)
Recurrent SAB infection 4 (11.8) 1 (2.9)
Death due to SAB infection 3 (8.8) 0 (0.0)
Death due to other causes 0 (0.0) 0 (0.0)
For metastatic infection, some patients have more than 1 type of metastatic infection. Some patients have
more than 1 type of procedure used to treat the infection. APACHE II, Acute Physiology and Chronic Health
Evaluation II; GI/GU, gastrointestinal/genitourinary; HCA, health care associated; LOS, length of stay; P, percentile.
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Inhibition of DNA Methylation Also Increases IL-10 Production in
Human Macrophages. Because of the documented role of DNMT3A
in DNA methylation (18) and our finding that A/C heterozygotes
had higher methylation levels, we next evaluated the role of DNA
methylation on human macrophage cytokine response to S. aureus.
To do this, human macrophage methylation was inhibited by
pretreatment with 5-Aza-2′-deoxycytidine (DAC), a drug known to
inhibit DNAmethyltransferase (19). Consistent with the increases in
IL-10 production elicited by S. aureus challenge of human macro-
phages with siRNA knockdown of DNMT3A, inhibiting the meth-
ylation capacity of human macrophages also caused significant
increases in IL-10 production after S. aureus challenge (DAC
treatment: 353.19 pg/mL vs. phosphate-buffered saline (PBS)
treatment: 235.62 pg/mL; P = 0.0209) (Fig. 6B and SI Appendix,
Fig. S4B). These data agree with our working model (Fig. 5) and
further support a role of DNMT3A in regulating cytokine pro-
duction, possibly mediated by changes in DNA methylation.
Methylation Inhibition in Mice Confers Susceptibility to S. aureus
Infection. To further elucidate the importance of DNMT3A-
mediated methylation in host response to S. aureus, we inhibited
methylation capacity in mice by pretreatment with DAC followed
by infection with S. aureus. DAC-treated mice exhibited signifi-
cantly greater mortality than PBS-treated controls following chal-
lenge with either methicillin-susceptible S. aureus (Fig. 7A) or MRSA
(Fig. 7B). Bacterial load was significantly higher in the kidney,
spleen, liver, and lung of DAC-treated mice than infected PBS-
treated controls (Fig. 7C). DAC-treated mice also exhibited higher
serum concentration of cytokines/chemokines than PBS-treated
controls overall, although none of these differences achieved the
level of statistical significance (SI Appendix, Fig. S5). These results
suggest that methylation capacity is vital in mice to control S.
aureus infection.
MRSA Isolates from Patients with PB and RB Elicit Similar Cytokine
Response from Primary Human Macrophages but Different Levels of
Macrophage Uptake. To test whether the associations between
DNMT3A polymorphisms and the PB clinical phenotype might
be specific to the infecting bacterial isolates rather than host
response, we challenged primary human macrophages with rep-
resentative PB or RB isolates (n = 5 of each) and assessed up-
take and the elicited cytokine response using a 25-plex Luminex
array. PB isolates exhibited significantly reduced median levels
of phagocytosis by primary human macrophages compared with
RB isolates (45,111.11 vs. 66,666.67 colony-forming unit [cfu]/mL;
P = 0.0292) (Fig. 8). When we conducted the experiment with
extended incubation to 24 h, RB isolates were again isolated in
higher numbers from macrophages than PB isolates, although the
difference did not achieve statistical significance (SI Appendix, Fig.
S6). In the 25-plex Luminex array, only IL-8 production differed
significantly in primary human macrophages challenged by PB
isolates vs. RB isolates (12,610.6 vs. 14,764.4 pg/mL; P = 0.0008)
(SI Appendix, Fig. S7).
Discussion
This study demonstrates that a specific polymorphism inDNMT3A
is associated with a reduced risk for persistent MRSA bacteremia
in patients, potentially through reducing IL-10 response by way of
enhanced methylation. These conclusions are based on the fol-
lowing experimental evidence. First, g.25498283A > C inDNMT3A
was associated with the RB phenotype at a level of significance
of P = 7.8 × 10−6. Second, DNMT3A expression was suppressed
by S. aureus in both primary human macrophages challenged with
Fig. 1. Polymorphism in DNMT3A is associated with persistent MRSA bacteremia. The Manhattan plot of the P values from all SNPs. The x axis shows the
chromosome numbers, and the y axis is the −log10 (P value). One SNP, g.25498283A > C in DNMT3A, was our most significant variant (red box). The top
20 variants (to P < 10−3) are provided in SI Appendix, Table S1.
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S. aureus and patients with SAB. Third, IL-10 levels were signifi-
cantly higher in patients with PB and among patients without
the g.25498283A > C SNP inDNMT3A. Fourth, inhibition of both
DNMT3A transcription and methylation activity led to increased
IL-10 production by human macrophages upon S. aureus stimu-
lation. Fifth, overall DNA methylation in patients with the
g.25498283A > C mutation in DNMT3A was increased within
gene-regulatory regions and was consistent with expectations
based on our in vitro studies of DNMT3A. Sixth, methylation in-
hibition in mice rendered them significantly more susceptible to S.
aureus. Collectively, these findings support the observation that
DNAmethylation is important for protective host immune defenses
against S. aureus by way of a mechanism outlined in our working
model (Fig. 5).
Although the mechanism remains incompletely understood,
the observed association between g.25498283A > C mutation in
DNMT3A and PB is consistent with previous studies. Cao et al.
(20) found that a polymorphism in DNMT3A was associated with
increased risk of Helicobacter pylori infection, a gram-negative
bacterium responsible for gastric cancer. Other investigators
have shown that mice deficient in Dnmt3a were susceptible to
vesicular stomatitis infection (21) via impaired production of
type I interferons (IFNs; IFN-α and IFN-β) (22). In T cells,
Dnmt3a is known to regulate cytokine production with IL-13, in
particular being increased in the absence of Dnmt3a but not
Dnmt3b (23). These data extend insights in this regard to S. aureus,
as IL-13 is a hallmark of Th2 immune responses that recent vaccine
studies suggest do not adequately protect against S. aureus (24).
Likewise, in mast cells, loss of Dnmt3a is accompanied by increased
IL-13, IL-6, and tumor necrosis factor-α (TNF-α) production after
stimulation with Immunoglobulin E antigen (10). However, as
transforming growth factor-β (TGF-β) is required along with IL-
6 and TNF-α to induce protective Th-17 polarization, change-in-
function polymorphisms of DNMT3A could alter protective im-
munity against S. aureus. It has also been shown that mice with B
cells deficient in Dnmt3a/Dnmt3b have increased cell activation
when immunized with phycoerythrin emulsified in complete Freud’s
adjuvant (25). Consistent with the pattern of generally increased
cytokine production in DNMT3A-deficient cells, we found that
siRNA knockdown of DNMT3A or inhibition with DAC in human
macrophages resulted in increased levels of cytokine IL-10
production upon S. aureus stimulation.
IL-10, an immunosuppressive cytokine produced primarily in
the Th2 paradigm, has been identified as a potential marker of
immune dysregulation associated with persistent SAB and/or
mortality (15). IL-10 is known to block the activation of
Th1 cells, thereby promoting susceptibility to certain in-
tracellular pathogens (26, 27). One role for IL-10 is in regulation
of the production of proinflammatory cytokines and has been
shown to play an essential role during S. aureus infection: too
much IL-10 expression biases toward death of the infected host
(28). IL-10 has also been shown to inhibit microbial killing by
limiting the production of reactive oxygen and nitrogen inter-
mediates (29, 30). In Mycobacterium tuberculosis infection, IL-10
blocks phagosome maturation and facilitates M. tuberculosis
survival (31). Transgenic mice overexpressing IL-10 in T cells are
more susceptible to M. tuberculosis infection (32). Elevation in
serum IL-10 has also been described in humans with active
Fig. 2. DNMT3A transcription is suppressed by S. aureus. (A) Expression pattern of DNMT3A between patients with SAB, E. coli bacteremia, and uninfected
control subjects. Human blood RNA from patients in each group was extracted and subjected to microarray. NS: not significant. (B) Macrophages were
challenged with S. aureus at a multiplicity of infection of 10 for 5 h. Total RNA was extracted, and the expression of DNMT3A was determined by real-time
PCR and normalized to that of Actin. Data are presented as the average and SD of points from 7 biological replicates. (C) Human macrophages data from
public dataset GEO:GSE13670 were analyzed. DNMT3A was suppressed by S. aureus at all times tested compared with uninfected control. Data are presented
as the average and SD of points from 5 biological replicates. SA: S. aureus. (D) Human neutrophils data from public dataset GEO:GSE16837 were analyzed.
DNMT3A was suppressed by S. aureus at 2 and 3 h compared with 0-h control. For 0-h control, n = 4, and for 2 and 3 h, n = 27. Significance was determined
using the Mann–Whitney U test. **P < 0.01; ***P < 0.001.
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pulmonary tuberculosis (33), thereby establishing a direct cor-
relation between IL-10 level and disease severity.
Our study had limitations. First, the polymorphism is located
in the noncoding region of DNMT3A. Thus, it is not possible to
predict any direct effect of the polymorphism on DNMT3A
function. Second, the mutation did not impact the transcription
of DNMT3A messenger RNA (mRNA); therefore, the siRNA
model system used in this manuscript may not accurately rep-
resent the effect of the polymorphism observed with WES. Our
proof of concept study using DAC-treated mice has the potential
for broader, off-target effects of DAC. Thus, additional experi-
ments are underway in our laboratory to determine the specific
association between DNMT3A polymorphisms and persistent S.
aureus infection using knockout mice. Third, we recognize that
certain subsets of IL-10–producing CD4+ T cells are proin-
flammatory (34). Thus, IL-10 should not be exclusively defined
as antiinflammatory; rather, IL-10 likely functions in context of
other responses that collectively shape protective vs. nonprotective
immunity to a given pathogen in a specific host. Fourth, the causes
of persistent MRSA bacteremia are complex. For example, we
found that bacteria from patients with PB and RB interacted
differently with human macrophages, eliciting different levels of
phagocytosis and triggering different levels of IL-8 from these
cells. Thus, it is likely that a number of clinical and bacterial
characteristics in addition to the patient’s DNMT3A genotype
may also contribute to this clinical syndrome. Fifth, there are
undoubtedly additional cytokines or other molecular and cellular
immune responses not presently studied that contribute to the PB
vs. RB outcome. Susceptibility to host defense peptides and
binding to endothelial cells are 2 examples of MRSA phenotypes
that also seem to influence PB vs. RB outcomes (35).
Despite these limitations, this study provides evidence that the
g.25498283A > C polymorphism in DNMT3A protects against per-
sistent MRSA bacteremia by changing patterns in DNA methylation.
The findings establish epigenetic modification of DNA as influencing
host response to S. aureus infection. Future studies are underway to
elucidate the molecular mechanisms of how this polymorphism in-
fluences the risk for PB. The ability of advanced bioinformatics tools
to assess global genome methylation patterns across all regions of the
human genome will greatly facilitate this goal.
Material and Methods
Clinical Cohort. The S. aureus Bacteremia Group Prospective Cohort Study has
prospectively enrolled all eligible adult, hospitalized, nonneutropenic pa-
tients with monomicrobial SAB at Duke University Medical Center since
September 1994. Patients were excluded from the study if they were <18 y
of age, were neutropenic (defined as an absolute neutrophil count ≤1 × 109/L),
were not admitted to the hospital, were previously enrolled for another
Fig. 3. Polymorphism in DNMT3A-dysregulated DNA methylation in patients. The DNA methylation levels in PB and RB patients were measured by RRBS. The
violin plot shows the distribution of the CpG counts at each average methylation level for patients without the mutation (A/A [green]: n = 44) and patients
with the g.25498283A > C mutation (A/C [salmon]: n = 24). The median test was computed to compare the differences between patients with and without
g.25498283A > C mutation. Patients with the g.25498283A > C mutation exhibited significantly higher levels of methylation in gene-regulatory CpG island
regions than patients with the homozygote genotype (Δmethylation = 4.1%; P < 0.0001).
Fig. 4. Serum IL-10 concentration is lower in patients with A/C genotype
than A/A. Serum cytokine production was determined using human 38-plex
magnetic cytokine/chemokine kits. Before testing, IL-10 levels (picograms
per milliliter) were log transformed to satisfy normality assumptions and to
mitigate variance heterogeneity. **P < 0.01 (A/C: n = 24 and A/A: n = 44).
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SAB episode, had no signs or symptoms of infection, had an additional
clinically significant bacterial pathogen that was isolated from their blood
culture, or declined informed consent. Only the initial presentation for eli-
gible patients was included in the study. Clinical data were collected on a
standardized case report form and entered into an electronic database
(Microsoft Access). The outcomes of SAB per study protocol recorded deaths
(attributable to S. aureus or other causes), cure, or recurrent bacteremia
within the 90-d follow-up period. The study was approved by the Duke In-
stitutional Review Board. Written informed consent was obtained from
patients or their legal representatives. If a patient died prior to the notifi-
cation of their blood culture results, the subjects were included using an
Institutional Review Board-approved Notification of Decedent Research.
Patients were defined as having either PB or RB. PB patients (n = 34) had
ongoing MRSA bacteremia for at least 5 d after initiation of effective anti-
biotics. Patients with RB had initial blood cultures that were positive for
MRSA, but all subsequent blood cultures were sterile. PB and RB patients
were eligible for inclusion if all required biological samples were available
(sera/plasma, RNA, DNA, and bloodstream isolate), and they were success-
fully matched 1:1 by sex, age (by deciles), race, hemodialysis status, diabetes
mellitus, and presence of any implantable medical device using nearest
neighbor propensity scores (36) generated from logit regression models fit
separately across 4 strata.
WES and Analysis. DNA-Seq data were processed using the TrimGalore toolkit
(37) (v0.4.0), which uses Cutadapt (v1.8.3) to trim low-quality bases and
Illumina sequencing adapters from the 3′ end of the reads. Reads were
aligned to the b37 version of the human genome with the BWA algorithm
(v0.7.12). Alignment processing and variant calling were performed using
the GATK toolkit (v3.7) following the Broad Institute’s Best Practices
Workflow (38). Association testing was carried out using the Fisher’s exact
test from the RVTESTS algorithm (39) (v20150104).
RNA-seq in PB and RB Patients. Total RNA was isolated with the Qiagen RNA
Blood kit, and quality control was performed with Nanodrop 8000 and
Agilent Bioanalyzer 2100. Globin RNA was removed with the Life Tech-
nologies GLOBINCLEAR (human) kit. Libraries for RNA-seq were prepared
with the KAPA Stranded mRNA-Seq Kit. The workflow consists of mRNA
enrichment, complementary DNA (cDNA) generation, and end repair to
generate blunt ends, A tailing, adaptor ligation, and PCR amplification.
Different adaptors were used for multiplexing samples in 1 lane. Sequencing
was performed on an Illumina Hiseq3000 for a single-read 50 run. Each
sample gets an average of 15 million reads. Data quality check was done on
Illumina SAV. Demultiplexing was performed with the Illumina Bcl2fastq2
v 2.17 program.
DNAMethylation Levels in A/A and A/C Patients. The DNAmethylation levels in
patients with and without the g.25498283A > C mutation were measured by
RRBS as previously described (40). The detectable CpGs were determined
based on the filter of 15× coverage. The average methylation level for each
CpG in patients with or without g.25498283A > C mutation was calculated
using python package scipy. The violin plot demonstrated the distributions
of the CpG counts at each averaged methylation level generated by python
library seaborn. The median test was computed to compare the differences
between patients with and without g.25498283A > C mutation in STATA.
Serum/Plasma 38-Plex Cytokine/Chemokine Array. Luminex assay and analysis
were performed by the University of California, Los Angeles Immune As-
sessment Core. Human 38-plex magnetic cytokine/chemokine kits (EMD
Millipore; HCYTMAG-60K-PX38) were used per the manufacturer’s instruc-
tions. Fluorescence was quantified using a Luminex 200 instrument. Cyto-
kine/chemokine concentrations were calculated using Milliplex Analyst
software version 4.2 (EMD Millipore).
Measurement of Cytokines in In Vitro Assays. Cytokine production was assayed
from the supernatant of either S. aureus-challenged siRNA-transfected
macrophages or S. aureus-challenged DAC-treated macrophages using a
multiplex cytokine kit and Luminex technology available at the Duke Human
Vaccine Institute. Ten cytokines were tested: TNF-α, IL-1β, IL-2, IFN-γ, IL-4, IL-
5, IL-6, IL-10, IL-8, and granulocyte-macrophage colony-stimulating factor
(GM-CSF). Of the 10 tested cytokines, 5 for siRNA (IL-1β, IL-5, IFN-γ, IL-2,
and IL-4) and 6 for DAC (IL-1β, IL-5, IFN-γ, IL-2, IL-4, and GM-CSF) were ex-
cluded from our analysis due to lack of response to S. aureus; 1 cytokine GM-
CSF for siRNA and 1 cytokine TNF-α for DAC were excluded for weak signal
or unproven running, and 1 cytokine (IL-8 for both siRNA and DAC) was
excluded for cross-contamination (SI Appendix, Fig. S3). For cytokines/che-
mokines production in human macrophages challenged with persistent and
resolving isolates, 25 cytokines were tested: IL-1β, IL-10, IL-6, RANTES,
Eotaxin, IL-17A, MIP-1α, GM-CSF, MIP-1β, MCP-1, IL-15, IL-5, IFN-γ, IFN-α, IL-
1RA, TNF-α, IL-2, IL-7, IP-10, IL-2R, MIG, IL-4, IL-8, IL-12, and IL-13. Of those, 9
(IL-1β, RANTES, Eotaxin, IL-17A, GM-CSF, IL-5, IL-2, IL-7, and IL-13) were ex-
cluded from our analysis due to lack of response to S. aureus; 2 (IP-10 and
IFN-γ) were excluded for weak signal, and 3 (IL-1RA, IFN-α, and MCP-1) were
excluded cross-contamination.
Fig. 5. Working model of DNMT3A polymorphism and persistent MRSA
bacteremia.
Fig. 6. (A) siRNA knockdown or (B) DAC treatment of human macrophages increases IL-10 production. Primary human macrophages were treated with either
DNMT3A siRNA or DAC, then incubated with S. aureus at a multiplicity of infection of 10 for 5 h, after which macrophage culture supernatants were collected
for cytokine analysis. The IL-10 profile was determined by Luminex-based multiplex cytokine assay. Data are presented as the average and SD of points from
4 biological replicates. Significance was determined using the Mann–Whitney U test. *P < 0.05.
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Bacterial Strains and Growth Conditions. Sanger 476, a methicillin-susceptible
S. aureus (41), and LAC, an MRSA isolate (42), were used in this study. S.
aureus was prepared as previously described (43) with minor modifications.
After overnight culture, an appropriate number of cells were diluted to
500 mL fresh tryptic soy broth to achieve an optical density at wavelength
600 nm (OD 600) of 0.1. The flasks were incubated at 37 °C and 220 rpm to
log-phase growth (OD 600 ∼ 1.0). Cells were harvested by centrifugation,
washed twice with PBS, resuspended in PBS containing 20% glycerol to a
concentration of ∼106 cfu/μL, aliquoted into individual cryovials, and im-
mediately stored at −80 °C until further use. An aliquot of PBS-washed
culture was serially diluted and plated on Trypticase soy agar plates to
enumerate cfu. Frozen stocks were titered for cfu in triplicate on separate
occasions before use in any experiment.
Mammalian Cell Culture. Primary human macrophages were derived from
peripheral blood monocytes isolated from whole blood taken from healthy
volunteers (Nebraska Medical School). Monocytes were cultured in Dulbecco’s
Modified Eagle’s Medium containing 10% (vol/vol) true pooled human
serum (serocase) supplemented with 0.1% gentamycin (Sigma) and re-
combinant human macrophage colony-stimulating factor (M-CSF) at 6 ng/mL
(RD systems). After 3 d of culture, fresh medium was added to dilute out
M-CSF and antibiotic, and every other day, half of the medium was replaced
with fresh medium for up to 7 d, at which point cells were ready for
functional study.
siRNA Transfection. Differentiated primary human macrophages were
transfected with either siRNA targeting DNMT3A or control scramble siRNA
(Dharmacon). Stocks of siRNA along with the scramble siRNA were diluted to
10 μM with RNase free water. Prior to transfection, siRNAs were added to
Opti-MEM (Thermo Fisher Scientific); then, the solution was combined with
lipofectamine RNAiMAX (Thermo Fisher Scientific) and incubated at room
temperature for 10 min for complex formation. After the siRNAs complex
was added to the cells to a final concentration of 50 nM and cells were in-
cubated in a 37 °C and 5% CO2 incubator for 24 h, the cells were washed
with PBS and then, challenged with S. aureus. The efficiency of DNMT3A
knockdown was measured by qRT-PCR.
Fig. 7. Mice treated with DAC are hypersusceptible to S. aureus with high bacterial tissue burden. (A) Survival curve of 8-wk-old C57BL/6NJ-DAC and
C57BL/6NJ-PBS mice after intraperitoneal injection of 108 cfu of methicillin-susceptible S. aureus (MSSA) strain Sanger 476 per mouse (n = 15 per group).
(B) Survival curve of 8-wk-old C57BL/6NJ-DAC and C57BL/6NJ-PBS mice after intraperitoneal injection of 4 × 107 cfu of methicillin-resistant S. aureus
(MRSA) LAC strain per mouse (C57BL/6NJ-DAC, n = 10; C57BL/6NJ-PBS, n = 9). Survival analysis was done using the log rank test (P < 0.001). (C ) Increased
bacterial load in DAC-treated and PBS-treated mice after S. aureus infection. DAC-treated and PBS-treated controls were injected intraperitoneally with
S. aureus strain Sanger 476, and the bacterial loads in kidneys, spleens, livers, and lungs were determined 18 h postinfection. Significant difference in
bacterial load between DAC-treated and PBS-treated control mice was done using the Mann–Whitney U test (P < 0.05). At least 4 mice per group were
analyzed.
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DAC Treatment of Human Macrophages. Cells were seeded at a density of 5 ×
105 cells per well in a 24-well plate (VWR). Dissolved DAC (Sigma) was added
to cells to achieve a final concentration of 5 μM, and cells were incubated in
a 37 °C and 5% CO2 incubator for 72 h. After the treatment, the medium was
replaced with fresh medium without DAC, and the cells were challenged
with S. aureus.
RNA Extraction, cDNA Conversion, and qRT-PCR. Total RNA was extracted using
the Direct-zol RNA MiniPrep kit (Zymo Research) and was subsequently
digested with DNase I (Zymo Research). The concentration and purity were
evaluated using the NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies). RNA was reverse transcribed using the SuperScript III Reverse
Transcriptase Kit (Thermo Fisher). qRT-PCR was performed using a Power SYBR
Select Mater Mix (Life Technologies) and an ABI Prism 7500 Fast real-time PCR
system (Life Technologies). All kits were used according to the manufacturer’s
instructions. The mRNA of DNMT3A was normalized to Actin ribosomal RNA.
The DNMT3A and Actin primers used here are as follow: DNMT3A (5′-TATT-
GATGAGCGCACAAGAGAGC-3′/5′-GGGTGTTCCAGGGTAACATTGAG-3′) and
Actin (5′-CACCAACTGGGACGACAT-3′/5′-ACAGCCTGGATAGCAACG-3′).
In Vivo Experiment. C57BL/6NJ mice were purchased from the Jackson Lab-
oratory and housed in a specific pathogen-free facility. The experimental
protocolwas approved by theDukeUniversity Animal Care andUse Committee,
and animals were handled in accordance with their guidelines. Mice were
injected via an intraperitoneal route with DAC (44) at a dose of 0. 2 mg/kg in
100 μl PBS for 5 consecutive days. Controls mice were given an appropriate
volume of PBS. After treatment, both groups were challenged via the in-
traperitoneal route with S. aureus strains and monitored for morbidity every
8 h for a total of 5 d.
Tissue Bacterial Culture. For tissue bacterial culture, mice were euthanized at
18 h postinjection. Tissues were isolated and weighed under sterile condi-
tions, and they were homogenized in PBS followed by serial dilution; each
dilution was plated on Tryptic Soy Agar (Becton Dickinson). Plates were in-
cubated overnight at 37 °C; the number of colonies was counted and mul-
tiplied by the corresponding dilution factor, and the result is expressed as
cfu per gram.
5-Methylcytosine Measurements. Briefly, genomic DNA (gDNA) was isolated
from mice tails using a DNeasy Blood & Tissue Kit (Qiagen). The gDNA
(100 ng) was coated with 5-methylcytosine (5-mC) coating buffer and then,
immediately denatured at 98 °C for 5 min in a thermal cycler. The de-
naturing DNA was blocked with 5-mC Elisa buffer, and 5-mC levels in gDNA
were determined using and anti–5-mC antibody (Zymo Research).
Statistical Analysis. Standard t tests were conduct via STATA (45) to compare
mean IL-10 levels among mutant and wild-type Dnmt3a individuals. Before
testing, IL-10 levels (picograms per milliliter) were log transformed to satisfy
normality assumptions and to mitigate variance heterogeneity. All P values
were 2 sided, and no adjustment for multiple comparisons was made here.
(For completeness, the additional tests comparing Dnmt3a groups for PB and
RB subgroups were formulated post hoc and are considered exploratory.)
Demographic and clinical characteristics for the persistent and resolving
bacteremia patients as well as for the DNMT3A genotype groups are pre-
sented as counts and percentages for categorical variables and as medians
and quartiles for the continuous measures. Statistical comparisons comparing
the groups were performed with Fisher’s exact test and theMann–Whitney U
test as appropriate. Differences in experimental results for continuous
measures were also compared with the Mann–Whitney U test, and statistical
differences in survival of experimental are displayed as Kaplan–Meier curves
and tested with the log rank test. P values of <0.05 were considered statisti-
cally significant. These analyses were conducted with SAS 9.4 (SAS Institute).
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